Vesugen
Khavinson tripeptide bioregulator (Lys-Glu-Asp) targeting vascular endothelium — studied for improving vessel wall function, reducing atherosclerosis progression, and normalizing blood flow.
🔬 Mechanism of Action
Vesugen (Lys-Glu-Asp, KED) is a synthetic tripeptide bioregulator targeting vascular endothelium, identified through Khavinson's systematic isolation of tissue-specific peptide sequences from blood vessel extracts. The KED sequence demonstrated the highest endothelial cell gene-activating potency among candidate tripeptides.
Vesugen modulates expression of endothelial nitric oxide synthase (eNOS) — the enzyme producing NO for vasodilation — along with vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and extracellular matrix proteins including elastin and collagen type IV.
In aged rat models, 10-day Vesugen treatment restored aortic eNOS expression to levels comparable to young controls and reduced vascular intima-media thickness by approximately 20%. Vesugen is the synthetic counterpart to Ventfort — the natural Cytomax vascular extract.
Source: PMID: 15677927
📜Background & History
Vesugen (Lys-Glu-Asp) targets vascular endothelium for eNOS and extracellular matrix maintenance.
🎯 Research Use Cases
- ✓Vascular health
- ✓Atherosclerosis prevention
- ✓Endothelial function restoration
💉 Dosing Protocol
| Typical Dose | 10-20 mg/day (oral) or 1-2 mg SC |
| Frequency | 1× daily for 10-30 day cycles |
| Half-Life | ~30 minutes (estimated) |
| Common Vial Sizes | 5 mg, 10 mg |
🧪 Reconstitution Example
⚠️Safety & Considerations
Standard Khavinson protocol. Well tolerated. Can be combined with Ventfort (vascular Cytomax extract) for comprehensive vascular support.
⚡Interactions & Contraindications
Standard Khavinson protocol.
🔗Synergies & Common Stacks
Vesugen (synthetic) + Ventfort (vascular Cytomax) = comprehensive vascular support.
Vesugen (vessels) + Cardiogen (heart) = comprehensive cardiovascular bioregulator protocol.